Authors: Maria Tsirigotis, R. Mitchell Baldwin, Matthew Y. Tang, Ian A. J. Lorimer, Douglas A. Gray
DOI: 10.1371/journal.pone.0002130
Abstract Summary
Researchers identify p38MAPK as a key driver of cell death in polyglutamine diseases like spinocerebellar ataxia. Blocking p38MAPK rescued cells from toxicity, while PKCι protein protected cells by activating the ERK pathway. These findings, confirmed in both cell cultures and animal models, suggest p38MAPK inhibition could offer a promising therapeutic strategy for treating polyglutamine disorders.
Why Brain? 🧠
Study identifies p38MAPK enzyme as key driver of cell death in polyglutamine diseases like spinocerebellar ataxia, suggesting blocking this pathway could offer new treatment approach.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
